THU0088 Structural Damage Progression in Patients Treated With Methotrexate, Baricitinib Monotherapy or Baricitinib + Methotrexate Based on Their Level of Clinical Response in the Phase 3 Ra-Begin Study
doi 10.1136/annrheumdis-2017-eular.2223
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism